DSCSA Compliance: Is Your Organization Ready for 2026 & Beyond?

The Short Answer: DSCSA compliance requires every trading partner in the pharmaceutical supply chain to exchange transaction data electronically, apply a product identifier to each package, and verify products at the package level. Manufacturers, repackagers, wholesale distributors, and large dispensers are already fully in scope, and small dispensers face a final deadline of November 27, 2026.

The Drug Supply Chain Security Act became law in 2013 to secure the drug supply chain and reduce the risk of an illegitimate product reaching patients in the United States. The law gives the Food and Drug Administration more authority over product tracing and verification at every stop along the drug lifecycle.

After years of staggered deadlines and a stabilization period, the 2026 picture is much simpler than it was two years ago. Most of the pharmaceutical industry is past its exemption date. Small dispensers are the last group still operating under time-limited relief, and the FDA has signaled that no further extensions are coming.

What Is the Drug Supply Chain Security Act?

DSCSA is Title II of the Drug Quality and Security Act (DQSA), signed in 2013. It created a national standard for tracking prescription drugs as they move through the pharmaceutical supply chain.

Why the Law Was Introduced

DQSA has two parts:

• Title I (Compounding Quality Act): a response to the 2012 meningitis outbreak tied to the New England Compounding Center, which caused 64 deaths.
• Title II (DSCSA): standardized processes for tracing and verifying prescription drugs.

The goal of Title II is to keep patients safe from harmful drugs, including counterfeit medicine, by making product tracing possible at the package level.

How DSCSA Rolled Out

The law was built in phases. Phase I set the foundation: work only with authorized trading partners, pass transaction documentation with every change of ownership, and investigate suspect product. Phase II added the enhanced drug distribution security requirements, which call for an interoperable system that tracks individual packages electronically.

Full enforcement of the enhanced requirements was originally set for November 2023. The FDA announced a one-year stabilization period in August 2023 to give trading partners additional time. In October 2024, the agency issued a second round of exemptions organized by trading partner type.

DSCSA Compliance Deadlines: Where Things Stand in 2026

The October 2024 exemptions applied only to eligible trading partners that had already made complete data connections with their immediate trading partners but still faced data exchange problems. Those dates have now passed for almost everyone:

• Manufacturers and repackagers: May 27, 2025
• Wholesale distributors: August 27, 2025
• Large dispensers (26 or more full-time pharmacists or pharmacy technicians): November 27, 2025
• Small dispensers (25 or fewer full-time pharmacists or pharmacy technicians): November 27, 2026

A dispenser qualifies as a small dispenser based on the total staff count of the corporate entity that owns it, so pharmacies under common ownership are counted together. No filing is required to claim it, but a pharmacy has to determine its own eligibility correctly.

What the Small Dispenser Exemption Does Not Cover

The exemption applies only to the enhanced drug distribution security requirements. Every foundational DSCSA obligation stays in effect right now, including:

• Buying and selling only with authorized trading partners
• Handling product that carries a valid product identifier
• Receiving, storing, and providing lot-level transaction data
• Investigating and quarantining suspect or illegitimate product

Core DSCSA Requirements

Transaction Data

Three documents move with every change of ownership:

• Transaction information: product name, dosage form and strength, container size, transaction date, lot number, number of containers, National Drug Code, and the names and addresses of both businesses.
• Transaction history: a record tracing the transaction information back through all previous transactions, including the manufacturer. This requirement was retired for most partners once enhanced tracing took effect, replaced by package-level data exchange.
• Transaction statement: a statement from each business confirming it meets DSCSA requirements and is authorized to transfer the product.

Under the enhanced requirements, this data has to move in a secure, electronic, interoperable manner, typically in GS1 EPCIS format. Paper and mixed methods no longer meet the standard.

Product Identifier

Manufacturers and repackagers apply a product identifier to every package and homogenous case. It contains:

• Standardized numerical identifier (NDC plus a unique serial number)
• Lot number
• Expiration date

The identifier appears in both human-readable text and a 2D data matrix barcode.

Verification Requirements

Product verification means confirming that the product identifier on a package matches what the manufacturer issued. Trading partners verify saleable returns before redistributing them, and all partners verify product identifiers during suspect product investigations. Package-level transaction information has to be available to the FDA within 24 hours of a request.

DSCSA Compliance Requirements by Role

Manufacturers

Manufacturers serialize at the point of packaging, maintain the data that supports downstream verification, and respond to verification requests from other trading partners. They also notify the FDA and their partners within 24 hours of confirming an illegitimate product.

Repackagers

Repackagers carry the same obligations as manufacturers. They apply a new product identifier to every package or homogenous case they produce, keep the link between incoming and outgoing serial numbers, and maintain a process for identifying and quarantining suspect product.

Wholesale Distributors and Third-Party Logistics Providers

Wholesale distributors verify product at the package level, pass serialized transaction data downstream, and refuse transactions involving prescription drugs without a valid product identifier. A third-party logistics provider does not take ownership of product but still has to meet federal and state licensing standards and support data exchange.

Distributors are already rejecting saleable returns that cannot be matched to original transaction data, which creates real supply chain disruption for the pharmacies on the receiving end.

Dispensers and Pharmacies

A retail pharmacy or hospital pharmacy is the last stop before the patient. Dispensers buy only from licensed, authorized partners and store transaction data for every purchase. When product looks suspect, they quarantine it, investigate, and notify the FDA and their trading partners before it goes any further.

Once the enhanced requirements apply, dispensers also verify product identifiers at receipt and exchange package-level data electronically.

FDA Enforcement Is Already Active

The FDA has moved from implementation support to enforcement. Recent actions have centered on the basics rather than the technical edges of interoperability:

• Purchasing from unauthorized sources
• Handling product with no product identifier
• Keeping transaction data in proprietary formats that cannot be shared electronically

State boards of pharmacy in several states now check DSCSA compliance during license renewal, so a federal finding can carry state consequences.

How to Prepare Before November 27, 2026

1. Confirm your classification. Count full-time licensed pharmacists and qualified pharmacy technicians across all locations under common ownership.
2. Verify that every trading partner you buy from is authorized and licensed.
3. Choose a data exchange method that supports EPCIS and connect it to your wholesalers.
4. Test package-level verification on real inbound product before the deadline, not after.
5. Write standard operating procedures for suspect product investigation, saleable returns, and FDA data requests.
6. Check that your labeling and packaging equipment can print serialized, scannable product identifiers.

Starting early gives you a smooth transition instead of a scramble in November.

How MPI Supports DSCSA Compliance

MPI builds packaging and labeling systems that produce the serialized, scannable output DSCSA requires.

• Pak-EDGE® Barcode Labeling Software: prints individual packages with a unique serial number and barcode. Automatically populates manufacturer information by scanning the DSCSA barcode on the bottle. The advanced barcode builder adds fields and delimiters to create linear or 2D barcodes carrying expiration dates, lot numbers, and any other field your tracking process calls for. Pak-EDGE® also provides lot traceability for drugs and materials.
• Fluidose® Series 6 & FD-Pharma®: cost-effective liquid packaging solutions for hospital pharmacies, specialty pharmaceutical manufacturers, and CDMOs. Both options support daily packaging needs, clinical trials, early product development, small batch validation runs, and lower-volume production. Materials meet FDA regulation 21 CFR 177.1520, and USP UV light resistance standards, and all lidding is produced under Good Manufacturing Practices.
• Type III Drug Master File: MPI’s own DMF gives customers faster access to the regulatory documentation they need for an NDA or ANDA filing, instead of waiting weeks on vendors and sub-vendors.

Explore the full line of medication labeling systems and barcode packaging equipment to see how they fit your workflow.

Getting Ready for the Final Deadline

DSCSA compliance in 2026 comes down to three things: transact only with eligible trading partners, handle only product carrying a valid product identifier, and exchange transaction data electronically at the package level. Most of the pharmaceutical supply chain is already held to that standard. Small dispensers have until November 27, 2026, and the FDA has been clear that the date will not move again.

The organizations having the easiest time are the ones that tested their systems months before their deadline rather than days before it. Labeling accuracy is where much of that work starts, since a package that cannot be scanned and matched creates problems for every partner downstream.

MPI’s packaging and labeling systems produce accurate, serialized output that supports package-level tracking and regulatory compliance. Contact MPI to talk through your setup and find the right fit for your facility.

Resources

Center for Drug Evaluation and Research. “Drug Supply Chain Security Act (DSCSA).” U.S. Food and Drug Administration, www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa. Accessed 22 July 2026.

U.S. Food and Drug Administration. “Exemptions from Section 582(g)(1) and Other Requirements of Section 582 for Small Dispensers.” 12 July 2024, www.fda.gov/media/182584/download. Accessed 22 July 2026.

Center for Drug Evaluation and Research. “The Drug Supply Chain Security Act (DSCSA) Waivers, Exceptions, and Exemptions.” U.S. Food and Drug Administration, www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/drug-supply-chain-security-act-dscsa-waivers-exceptions-and-exemptions. Accessed 22 July 2026.

H.R.3204, 113th Congress (2013-2014): Drug Quality and Security Act. Congress.gov, Library of Congress, www.congress.gov/bill/113th-congress/house-bill/3204. Accessed 22 July 2026.

Office of Public Affairs. “14 Indicted in Connection with New England Compounding Center and Nationwide Fungal Meningitis Outbreak.” U.S. Department of Justice, www.justice.gov/archives/opa/pr/14-indicted-connection-new-england-compounding-center-and-nationwide-fungal-meningitis. Accessed 22 July 2026.

GS1 US. “Implementing GS1 Standards to Meet DSCSA Guidelines.” www.gs1us.org/industries-and-insights/by-industry/healthcare/standards-in-use/pharmaceutical/dscsa-implementation-guidelines. Accessed 22 July 2026.